Summary by Futu AI
On July 3, 2024, iBio Inc, a biotechnology company incorporated in Delaware, announced the entry into an At Market Issuance Sales Agreement (ATM Agreement) with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC. The agreement allows iBio to sell shares of its common stock from time to time through these sales agents. The offering is contingent upon the effectiveness of iBio's shelf registration statement on Form S-3, filed with the SEC on the same date. The company has set parameters for the sale, including the number of shares, the time period for sales, daily sales limits, and minimum sale price. The sales agents will sell the shares as defined by Rule 415(a)(4) on the NYSE American or any other...Show More